MedTrace Logo

Study of BCMA CAR-T in Multiple Myeloma

NCT03322735 · Status: UNKNOWN · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2017-12-29

No results posted yet for this study

Summary

The purpose of this study is to infusion BCMA CAR-T cells to the patients with relapsed and refractory multiple myeloma(MM), to assess the safety and feasibility of this strategy. The CAR enables the T cell to recognize and kill the MM cells through the recognition of BCMA, a protein expressed of the surface of the malignant plasma cells in MM patients.

Conditions

Interventions

DRUG

Fludarabine

25-30mg/m2/day IV for 3 days

DRUG

Cyclophosphamide

cyclophosphamide 0.6-0.8g/m2/day IV for 2 days

BIOLOGICAL

BCMA CAR-T

BCMA CAR-T cells will be administered after completion of the chemotherapy.

Sponsors & Collaborators

  • The Pregene (ShenZhen) Biotechnology Company, Ltd.

    collaborator INDUSTRY

  • Henan Cancer Hospital

    lead OTHER_GOV

Principal Investigators

  • Yongping Song · Henan Cancer Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-12-08
Primary Completion
2018-10-31
Completion
2019-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03322735 on ClinicalTrials.gov